Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06670521

Corticosteroids for Post-Extubation Dysphagia

Led by University of Colorado, Denver · Updated on 2026-05-06

80

Participants Needed

1

Research Sites

130 weeks

Total Duration

On this page

Sponsors

U

University of Colorado, Denver

Lead Sponsor

N

National Institute on Aging (NIA)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a placebo-controlled, double-blind randomized trial of a short course of intravenous corticosteroids for Acute Respiratory Failure Survivors with Fiberoptic Endoscopic Evaluation of Swallowing (FEES) documented laryngeal edema. Study was leveraged using the existing R01 grant infrastructure COMIRB # 21-3873, study design, and research methods. Patients for the study proposed will have already been enrolled in the R01 longitudinal cohort study. The sites to perform this study include Colorado, BU, Yale, Tufts, and Stanford. Those R01-enrolled patients with laryngeal edema on their initial FEES examination: defined as the revised Patterson edema score greater than zero, will be approached for enrollment.

CONDITIONS

Official Title

Corticosteroids for Post-Extubation Dysphagia

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant enrolled in primary study COMIRB #21-3873/ NCT # 05108896
  • Laryngeal edema identified on primary study FEES with a revised Patterson edema score greater than zero
  • Admission to an ICU during hospitalization
  • Mechanical ventilation with an endotracheal tube for more than 48 hours
  • Extubation except for compassionate extubation or transition to end-of-life care
Not Eligible

You will not qualify if you...

  • Patient or provider refusal
  • Allergic reaction to corticosteroids or taking other immunosuppressive medications
  • Chronic corticosteroid treatment (≥ 40 mg Prednisone/day or ≥32 mg Methylprednisolone/day)
  • Contraindication to enteral or oral nutrition
  • Pre-existing history of dysphagia or aspiration
  • Pre-existing or acute primary central or peripheral neuromuscular disorder
  • Presence of a chronic tracheostomy prior to ICU admission
  • Pre-existing head and neck cancer or surgery
  • Coagulopathy causing uncontrolled nasal or pharyngeal bleeding
  • Delirium as assessed by CAM-ICU
  • Inability to obtain informed consent from patient or surrogate
  • Age under 18 years

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Colorado

Aurora, Colorado, United States, 80045

Actively Recruiting

Loading map...

Research Team

A

Anna Matheson, BSN

CONTACT

J

Jeffrey McKeehan, MSN

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here